Logo image of 2X1.DE

ABIVAX SA (2X1.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:2X1 - FR0012333284 - Common Stock

102.2 EUR
-1.8 (-1.73%)
Last: 1/19/2026, 7:00:00 PM

2X1.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap8.02B
Revenue(TTM)N/A
Net Income(TTM)-176.24M
Shares78.44M
Float75.57M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-2.8
PEN/A
Fwd PEN/A
Earnings (Next)03-23
IPO2015-06-26
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
2X1.DE short term performance overview.The bars show the price performance of 2X1.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

2X1.DE long term performance overview.The bars show the price performance of 2X1.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 2X1.DE is 102.2 EUR. In the past month the price decreased by -5.01%.

ABIVAX SA / 2X1 Daily stock chart

2X1.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 2X1.DE.


Chartmill TA Rating
Chartmill Setup Rating

2X1.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to 2X1.DE. 2X1.DE has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

2X1.DE Financial Highlights

Over the last trailing twelve months 2X1.DE reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 18.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -146.87%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-23.26%
Sales Q2Q%N/A
EPS 1Y (TTM)18.52%
Revenue 1Y (TTM)N/A

2X1.DE Forecast & Estimates

14 analysts have analysed 2X1.DE and the average price target is 118.8 EUR. This implies a price increase of 16.25% is expected in the next year compared to the current price of 102.2.

For the next year, analysts expect an EPS growth of -20.7% and a revenue growth 91.53% for 2X1.DE


Analysts
Analysts85.71
Price Target118.8 (16.24%)
EPS Next Y-20.7%
Revenue Next Year91.53%

2X1.DE Ownership

Ownership
Inst Owners41.18%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

2X1.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ARGX.BR ARGENX SE 62.93 41.67B
1AE.DE ARGENX SE 63.81 42.04B
22UA.DE BIONTECH SE-ADR N/A 22.28B
ABVX.PA ABIVAX SA N/A 7.92B
GXE.DE GALAPAGOS NV N/A 1.80B
GLPG.AS GALAPAGOS NV N/A 1.81B
IVA.PA INVENTIVA SA N/A 1.01B
6IV.DE INVENTIVA SA N/A 1.05B
NANO.PA NANOBIOTIX N/A 871.73M
PHIL.MI PHILOGEN SPA 19.04 634.51M
FYB.DE FORMYCON AG N/A 409.06M
AYJ.DE VALNEVA SE N/A 365.15M

Related stock screener links

About 2X1.DE

Company Profile

2X1 logo image Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Company Info

ABIVAX SA

7-11 Boulevard Haussmann

Paris ILE-DE-FRANCE FR

Employees: 69

2X1 Company Website

2X1 Investor Relations

Phone: 33153830963

ABIVAX SA / 2X1.DE FAQ

What does ABIVAX SA do?

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.


What is the stock price of ABIVAX SA today?

The current stock price of 2X1.DE is 102.2 EUR. The price decreased by -1.73% in the last trading session.


Does 2X1 stock pay dividends?

2X1.DE does not pay a dividend.


How is the ChartMill rating for ABIVAX SA?

2X1.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the sector and industry classification for ABIVAX SA?

ABIVAX SA (2X1.DE) operates in the Health Care sector and the Biotechnology industry.


Can you provide the PE ratio for 2X1 stock?

ABIVAX SA (2X1.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.8).


When does ABIVAX SA (2X1.DE) report earnings?

ABIVAX SA (2X1.DE) will report earnings on 2026-03-23, after the market close.